keyword
MENU ▼
Read by QxMD icon Read
search

Dipeptidyl peptidase-4 inhibitor Drug class

keyword
https://www.readbyqxmd.com/read/27844335/cardiovascular-safety-of-incretin-based-therapies-in-type-2-diabetes-systematic-review-of-integrated-analyses-and-randomized-controlled-trials
#1
REVIEW
Edoardo Mannucci, Matteo Monami
INTRODUCTION: Regulatory requirements mandate that new drugs for treatment of patients with type 2 diabetes mellitus (T2DM), such as dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, are evaluated to show that they do not increase cardiovascular (CV) risk. METHODS: A systematic review was undertaken to evaluate the association between DPP-4 inhibitor and GLP-1 receptor agonist use and major adverse cardiac events (MACE)...
November 14, 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27835680/benefits-and-harms-of-sodium-glucose-co-transporter-2-inhibitors-in-patients-with-type-2-diabetes-a-systematic-review-and-meta-analysis
#2
Heidi Storgaard, Lise L Gluud, Cathy Bennett, Magnus F Grøndahl, Mikkel B Christensen, Filip K Knop, Tina Vilsbøll
OBJECTIVE: Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for the treatment of diabetes. We aimed at describing the maximal benefits and risks associated with SGLT2-i for patients with type 2 diabetes. DESIGN: Systematic review and meta-analysis. DATA SOURCES AND STUDY SELECTION: We included double-blinded, randomised controlled trials (RCTs) evaluating SGLT2-i administered in the highest approved therapeutic doses (canagliflozin 300 mg/day, dapagliflozin 10 mg/day, and empagliflozin 25 mg/day) for ≥12 weeks...
2016: PloS One
https://www.readbyqxmd.com/read/27817160/novel-anti-glycemic-drugs-and-reduction-of-cardiovascular-risk-in-diabetes-expectations-realized-promises-unmet
#3
REVIEW
James H Flory, Jenny K Ukena, James S Floyd
PURPOSE OF REVIEW: The purpose is to review evidence on cardiovascular risks and benefits of new treatments for type 2 diabetes mellitus. RECENT FINDINGS: In response to guidance issued by the Food and Drug Administration, thousands of patients have been enrolled in large randomized trials evaluating the cardiovascular effects of the three newest diabetes drug classes: glucagon-like peptide-1 (GLP-1) receptor agonists, sodium glucose cotransporter 2 (SGLT-2) inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors...
December 2016: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/27784818/effect-of-dipeptidyl-peptidase-4-inhibitor-in-patients-undergoing-bypass-surgery
#4
Shinji Ogawa, Yasuhide Okawa, Koshi Sawada, Yoshihiro Goto, Syunsuke Fukaya, Takahiko Suzuki
OBJECTIVES: Patients with diabetes mellitus often have more complicated postoperative courses and worse outcomes after coronary artery bypass grafting than those without this condition. Dipeptidyl-peptidase-4 inhibitors are a new class of oral medication for treating type 2 diabetes mellitus. We investigated how these drugs influence the postoperative course after coronary artery bypass in patients with type 2 diabetes mellitus. METHODS: We retrospectively reviewed the clinical records of 177 patients with type 2 diabetes who has undergone coronary artery bypass surgery between 2009 and 2013; 107 were treated with dipeptidyl-peptidase-4 inhibitors postoperatively, and 70 who did not receive dipeptidyl-peptidase-4 inhibitors served as a control group...
November 2016: Asian Cardiovascular & Thoracic Annals
https://www.readbyqxmd.com/read/27783546/risk-of-nondherence-to-diabetes-medications-among-medicare-advantage-enrollees-development-of-a-validated-risk-prediction-tool
#5
Shivani K Mhatre, Omar Serna, Shubhada Sansgiry, Marc L Fleming, E James Essien, Sujit S Sansgiry
BACKGROUND: Low adherence to oral antidiabetic drugs (OADs) in the Medicare population can greatly reduce Centers for Medicare & Medicaid Services (CMS) star ratings for managed care organizations (MCOs). OBJECTIVE: To develop and validate a risk assessment tool (Prescription Medication Adherence Prediction Tool for Diabetes Medications [RxAPT-D]) to predict nonadherence to OADs using Medicare claims data. METHODS: In this retrospective observational study, claims data for members enrolled in a Medicare Advantage Prescription Drug (MA-PD) program in Houston, Texas, were used...
November 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27779433/patient-preferences-for-diabetes-treatment-attributes-and-drug-classes
#6
Emuella M Flood, Kelly F Bell, Marie C de la Cruz, France M Ginchereau-Sowell
OBJECTIVE: To identify which treatment attributes are most influential in determining patient preferences for diabetes treatments and explore patient preferences for diabetes drug classes. RESEARCH DESIGN AND METHODS: US adults with type 1 or type 2 diabetes completed an online adaptive conjoint analysis survey. The survey examined 14 attributes, including efficacy, regimen, and risk of common side effects and rare but serious adverse events. Respondents selected between hypothetical treatments with different attributes...
December 2, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27585542/association-between-use-of-oral-antidiabetic-drugs-and-the-risk-of-aortic-aneurysm-a-nested-case-control-analysis
#7
Chien-Yi Hsu, Yu-Wen Su, Yung-Tai Chen, Shih-Hung Tsai, Chun-Chin Chang, Szu-Yuan Li, Po-Hsun Huang, Jaw-Wen Chen, Shing-Jong Lin
BACKGROUND: Pleiotropic effects on cardiovascular protection have been suggested in several oral antidiabetic drugs (OAD). The impacts of OADs on aortic aneurysm (AA) growth have been found in animal studies, but the evidence of their beneficial effects for AA protection in human are lacking. We investigated the relationship between OAD therapy and the risk of developing AA. METHODS: We conducted a nested case-control analysis using the database extracted from Taiwan's National Health Insurance Research Database...
2016: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/27520566/vildagliptin-induced-acute-lung-injury-a-case-report
#8
Nobumasa Ohara, Masanori Kaneko, Kazuhiro Sato, Ryoko Maruyama, Tomoyasu Furukawa, Junta Tanaka, Kenzo Kaneko, Kyuzi Kamoi
BACKGROUND: Dipeptidyl peptidase-4 inhibitors are a class of oral hypoglycemic drugs and are used widely to treat type 2 diabetes mellitus in many countries. Adverse effects include nasopharyngitis, headache, elevated serum pancreatic enzymes, and gastrointestinal symptoms. In addition, a few cases of interstitial pneumonia associated with their use have been reported in the Japanese literature. Here we describe a patient who developed drug-induced acute lung injury shortly after the administration of the dipeptidyl peptidase-4 inhibitor vildagliptin...
August 12, 2016: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/27502601/dpp-4-inhibitors-in-diabetic-complications-role-of-dpp-4-beyond-glucose-control
#9
REVIEW
Eun Ju Bae
Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are an emerging class of antidiabetic drugs that constitutes approximately fifty percent of the market share of the oral hypoglycemic drugs. Its mechanism of action for lowering blood glucose is essentially via inhibition of the rapid degradation of incretin hormones, such as glucagon-like peptide (GLP)-1 and gastric inhibitory polypeptide (GIP), thus the plasma concentration of GLP-1 increases, which promotes insulin secretion from the pancreatic β cells and suppresses glucagon secretion from the α cells...
August 2016: Archives of Pharmacal Research
https://www.readbyqxmd.com/read/27480840/angiotensin-converting-enzyme-inhibitor-use-and-major-cardiovascular-outcomes-in-type-2-diabetes-mellitus-treated-with-the-dipeptidyl-peptidase-4-inhibitor-alogliptin
#10
William B White, Craig A Wilson, George L Bakris, Richard M Bergenstal, Christopher P Cannon, William C Cushman, Simon K Heller, Cyrus R Mehta, Steven E Nissen, Faiez Zannad, Stuart Kupfer
Activation of the sympathetic nervous system when there is dipeptidyl peptidase 4 inhibition in the presence of high-dose angiotensin-converting enzyme (ACE) inhibition has led to concerns of potential increases in cardiovascular events when the 2 classes of drugs are coadministered. We evaluated cardiovascular outcomes from the EXAMINE (Examination of Cardiovascular Outcomes With Alogliptin versus Standard of Care) trial according to ACE inhibitor use. Patients with type 2 diabetes mellitus and a recent acute coronary syndrome were randomly assigned to receive the dipeptidyl peptidase 4 inhibitor alogliptin or placebo added to existing antihyperglycemic and cardiovascular prophylactic therapies...
September 2016: Hypertension
https://www.readbyqxmd.com/read/27479930/association-between-incretin-based-drugs-and-the-risk-of-acute-pancreatitis
#11
Laurent Azoulay, Kristian B Filion, Robert W Platt, Matthew Dahl, Colin R Dormuth, Kristin K Clemens, Madeleine Durand, Nianping Hu, David N Juurlink, J Michael Paterson, Laura E Targownik, Tanvir C Turin, Pierre Ernst, Samy Suissa, Colin R Dormuth, Brenda R Hemmelgarn, Gary F Teare, Patricia Caetano, Dan Chateau, David A Henry, J Michael Paterson, Jacques LeLorier, Adrian R Levy, Pierre Ernst, Robert W Platt, Ingrid S Sketris
Importance: The association between incretin-based drugs, such as dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) agonists, and acute pancreatitis is controversial. Objective: To determine whether the use of incretin-based drugs, compared with the use of 2 or more other oral antidiabetic drugs, is associated with an increased risk of acute pancreatitis. Design, Setting, and Participants: A large, international, multicenter, population-based cohort study was conducted using combined health records from 7 participating sites in Canada, the United States, and the United Kingdom...
October 1, 2016: JAMA Internal Medicine
https://www.readbyqxmd.com/read/27399082/trends-of-antidiabetic-drug-use-in-adult-type-2-diabetes-in-korea-in-2002-2013-nationwide-population-based-cohort-study
#12
Seung-Hyun Ko, Dae-Jung Kim, Jong-Heon Park, Cheol-Young Park, Chang Hee Jung, Hyuk-Sang Kwon, Joong-Yeol Park, Kee-Ho Song, Kyungdo Han, Ki-Up Lee, Kyung-Soo Ko
This study investigated trends in the prescription of antidiabetic medications for patients with type 2 diabetes, focusing on changing patterns of prescriptions and the cost of drugs during the last 10 years. Retrospective data on patients with type 2 diabetes aged 30 years or older were analyzed using information from the National Health Information Database collected by the National Health Insurance Service in Korea from January 2002 to December 2013. We identified patients with type 2 diabetes who had at least one service claim in each year during the study period...
July 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27389437/no-increased-risk-of-hospitalization-for-heart-failure-for-patients-treated-with-dipeptidyl-peptidase-4-inhibitors-in-taiwan
#13
Chia-Hsuin Chang, Yi-Cheng Chang, Jou-Wei Lin, James L Caffrey, Li-Chiu Wu, Mei-Shu Lai, Lee-Ming Chuang
BACKGROUND: Saxagliptin has been reported to be associated with an increased risk of hospitalization for heart failure (HF). The objective of this study was to test whether the increased risk is drug specific or a class effect for dipeptidyl peptidase-4 (DPP-4) inhibitors. METHODS: Diabetic patients prescribed sitagliptin, saxagliptin, and vildagliptin between 2011 and 2013 were identified from Taiwan's National Health Insurance (NHI) claims database. The outcome of interest was the first hospitalization for HF...
October 1, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27382338/the-treatment-of-type-2-diabetes-in-the-presence-of-renal-impairment-what-we-should-know-about-newer-therapies
#14
REVIEW
Melanie Davies, Sudesna Chatterjee, Kamlesh Khunti
Worldwide, an estimated 200 million people have chronic kidney disease (CKD), the most common causes of which include hypertension, arteriosclerosis, and diabetes. Importantly, ~40% of patients with diabetes develop CKD, yet evidence from major multicenter randomized controlled trials shows that intensive blood glucose control through pharmacological intervention can reduce the incidence and progression of CKD. Standard therapies for the treatment of type 2 diabetes include metformin, sulfonylureas, meglitinides, thiazolidinediones, and insulin...
2016: Clinical Pharmacology: Advances and Applications
https://www.readbyqxmd.com/read/27339889/pharmacology-and-therapeutic-implications-of-current-drugs-for-type-2-diabetes-mellitus
#15
REVIEW
Abd A Tahrani, Anthony H Barnett, Clifford J Bailey
Type 2 diabetes mellitus (T2DM) is a global epidemic that poses a major challenge to health-care systems. Improving metabolic control to approach normal glycaemia (where practical) greatly benefits long-term prognoses and justifies early, effective, sustained and safety-conscious intervention. Improvements in the understanding of the complex pathogenesis of T2DM have underpinned the development of glucose-lowering therapies with complementary mechanisms of action, which have expanded treatment options and facilitated individualized management strategies...
October 2016: Nature Reviews. Endocrinology
https://www.readbyqxmd.com/read/27321330/triple-therapy-combinations-for-the-treatment-of-type-2-diabetes-a-network-meta-analysis
#16
Crystal Man Ying Lee, Mark Woodward, Stephen Colagiuri
AIM: To estimate and compare the results from all randomised trials of triple combinations of anti-diabetes therapies that reported the reduction of glycated haemoglobin (HbA1c) and associated effects on body weight and hypoglycaemia. METHODS: PubMed and the Cochrane Library were searched for trials with at least one study arm on triple therapy and which reported the differences in mean change in HbA1c between two study arms. These were included in a network meta-analysis...
December 0: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/27268470/cardiovascular-effects-of-anti-diabetes-drugs
#17
Lisa M Younk, Elizabeth M Lamos, Stephen N Davis
INTRODUCTION: Cardiovascular disease remains the major contributor to morbidity and mortality in diabetes. From the need to reduce cardiovascular risk in diabetes and to ensure that such risk is not exacerbated by drug treatments, governmental regulators and drug manufacturers have focused on clinical trials evaluating cardiovascular outcomes. AREAS COVERED: Findings from mechanistic and clinical trials of biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose co-transporter 2 (SGLT-2) inhibitors will be reviewed...
September 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27188181/treating-diabetes-in-patients-with-heart-failure-moving-from-risk-to-benefit
#18
REVIEW
Ersilia M DeFilippis, Michael M Givertz
Over the past two decades, therapeutics for diabetes have evolved from drugs with known heart failure risk to classes with potential benefit for patients with heart failure. As many as 25 to 35 % of patients with heart failure carry a diagnosis of type 2 diabetes mellitus. Therefore, newer drug classes including dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GIP-1) agonists, and sodium-glucose cotransporter 2 (SGLT-2) inhibitors are being examined for cardiovascular safety as well as their effects on left ventricular function, quality of life, and other measures of disease progression...
June 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27114714/hypoglycemic-agents-and-potential-anti-inflammatory-activity
#19
REVIEW
Vishal Kothari, John A Galdo, Suresh T Mathews
Current literature shows an association of diabetes and secondary complications with chronic inflammation. Evidence of these immunological changes include altered levels of cytokines and chemokines, changes in the numbers and activation states of various leukocyte populations, apoptosis, and fibrosis during diabetes. Therefore, treatment of diabetes and its complications may include pharmacological strategies to reduce inflammation. Apart from anti-inflammatory drugs, various hypoglycemic agents have also been found to reduce inflammation that could contribute to improved outcomes...
2016: Journal of Inflammation Research
https://www.readbyqxmd.com/read/27107734/clinical-implications-of-cardiovascular-outcome-trials-in-type-2-diabetes-from-dcct-to-empa-reg
#20
Lars Rydén, Bahira Shahim, Linda Mellbin
Cardiovascular disease is a major threat to people with diabetes. Attempts have long been made to lower cardiovascular risk by means of glucose-lowering treatment. Initially, it seemed that was an option, but subsequent trials could not verify the original observations and there was concern that some glucose-lowering drugs can actually cause cardiovascular harm. This led medical product agencies in the United States and Europe to require major outcomes trials before accepting new glucose-lowering drugs. The least requirement was noninferiority compared with existing treatment modalities...
June 2016: Clinical Therapeutics
keyword
keyword
9532
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"